EyePoint, Inc. — Form 8-K
Filed October 19, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 72/100
What the filing says
EyePoint's LUCIA Phase 3 trial (475 patients) missed its primary non-inferiority endpoint for DURAVYU 2.7mg versus aflibercept in wet AMD: DURAVYU achieved +2.5 letter BCVA gain versus aflibercept's +6.1 letters (−3.7 letter difference, CI outside −4.5 letter non-inferiority margin). However, LUCIA met key secondary endpoints including 38% reduction in treatment burden (p=0.0001 nominal), 52% supplement-free rate through Week 56, and strong anatomic control (−66 μm CST reduction). Both Phase 3 wet AMD trials (LUGANO and LUCIA, ~907 patients total) failed primary endpoints despite secondary successes. Safety profile remained favorable. Company redirects focus to DME program; Phase 3 COMO and CAPRI trials expected to report topline in Q4 2027.
Why this rating
Primary endpoint failure eliminates wet AMD as viable near-term revenue path; company market cap ~$643M. However, secondary efficacy signals and ongoing DME trials partially offset. Material near-term setback.
Price action (we called it negative)
before filing · preread $2.99 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 19, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.